FDA advisory panel authorizes booster dose for those 65 & older

Yahoo Finance’s Anjalee Khemlani reports the FDA advisory panels' second vote regarding Covid-19 boosters.

Video Transcript

SEANA SMITH: We have more updates coming out of the FDA advisory panel meeting. Anjalee Khemlani has that for us, Anj?

ANJALEE KHEMLANI: That's right, Seana. We got a second vote out on booster doses. And the FDA advisory panel has recommended that anyone 65 and older and anyone at high risk of contracting COVID should be the recipients of a booster shot of the Pfizer vaccine. Now, this came as an emergency use authorization rather than a full approval, a recommendation for full approval, because this is a condition set on an already approved vaccine. And so that is where we see that change and that difference.

And so as it stands right now, the next steps are going to be that the CDC's advisory panel, which is set to meet next week, will define who those high-risk individuals are. Members of the advisory panel did note that the current framing of the recommendation does not cover health care workers or frontline workers. As we know, those are part of the highest risk to contract COVID.

SEANA SMITH: All right, Anjalee Khemlani, thanks so much for that, and certainly a story that we will keep on over the weekend and more updates, of course, next week.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting